^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NKT2152
i
Other names: NKT2152, NKT-2152, NKT 2152, HS10516
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Jiangsu Hansoh Pharma, NiKang Therap
Drug class:
HIF-2α inhibitor
Related drugs:
6ms
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
P1/2, N=128, Recruiting, NiKang Therapeutics, Inc. | N=98 --> 128
Enrollment change
|
PD-L1 (Programmed death ligand 1)
|
NKT2152
11ms
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) (clinicaltrials.gov)
P2, N=172, Not yet recruiting, NiKang Therapeutics, Inc.
New P2 trial • Combination therapy • Metastases
|
Ibrance (palbociclib) • sasanlimab (PF-06801591) • NKT2152
11ms
Clinical • P1/2 data • Metastases
|
NKT2152
over1year
A Phase 1/2, Open Label Dose- Escalation and Expansion Trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety. PK, PD and clinical activity in patients with advanced ccRCC (KCRS 2022)
The study is currently actively accruing in the United States. Methods N/A Results N/A Conclusions N/A
Clinical • P1/2 data
|
PD-L1 (Programmed death ligand 1) • VHL (von Hippel-Lindau tumor suppressor)
|
NKT2152
over2years
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
P1/2, N=98, Recruiting, NiKang Therapeutics, Inc.
New P1/2 trial
|
PD-L1 (Programmed death ligand 1)
|
NKT2152
Share via
